Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: A practice standard for Canadian nurses

Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: A practice standard for Canadian nurses

Show other versions (1)

<p class="p1">Azacitidine (5-azacytidine, VIDAZA<span class="s1">®</span>) is a disease-modifying agent that improves survival, reduces transfusion dependence, and reduces progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndrom...

Full description

Bibliographic Details
Main Authors:	Cindy Murray, Annie Wereley, Shannon Nixon, Carol Hua-Yung, Sarah von Riedemann, Sandra Kurtin
Format:	Article
Language:	English
Published:	Pappin Communications 2012-11-01
Series:	Canadian Oncology Nursing Journal
Online Access:	https://canadianoncologynursingjournal.com/index.php/conj/article/view/112

Similar Items

Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: A practice standard for Canadian nurses
by: Cindy Murray, et al.
Published: (2012-10-01)

Le counseling et la gestion des effets indésirables pour les patients ayant des syndromes myélodysplasiques traités à l’azacitidine : norme de pratique à l’intention des infirmières canadiennes
by: Cindy Murray, et al.
Published: (2012-11-01)

Safety and efficacy of azacitidine in myelodysplastic syndromes
by: Carlos E Vigil, et al.
Published: (2010-09-01)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
by: KS G&ouml;tze, et al.
Published: (2009-10-01)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
by: Konstantinos Liapis, et al.
Published: (2021-02-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
by: Eri Takada, et al.
Published: (2024-02-01)

5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE
by: I. Mandac Smoljanovic, et al.
Published: (2024-01-01)

MYELODYSPLASTIC SYNDROME RESPONDING TO THE AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMINS
by: VM Sthel, et al.
Published: (2023-10-01)

A Case of Organizing Pneumonia Following Azacitidine Treatment for Myelodysplastic Syndrome
by: Kelly Ann Hutchinson, et al.
Published: (2023-05-01)

Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine
by: Ai Yoshioka, et al.
Published: (2017-11-01)

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
by: Unnikrishnan, A, et al.
Published: (2017)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01)

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
by: Francesco D’Alò, et al.
Published: (2021-04-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
by: Ashwin Unnikrishnan, et al.
Published: (2017-07-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
by: Tomáš Stopka, et al.
Published: (2022-07-01)

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine
by: Shinichi Ogawa, et al.
Published: (2024-01-01)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
by: Andrius Žučenka, et al.
Published: (2023-08-01)

Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients
by: Marguerite-Marie Le Pannérer, et al.
Published: (2022-11-01)

Azacitidine Omega-3 Self-Assemblies: Synthesis, Characterization, and Potent Applications for Myelodysplastic Syndromes
by: Milad Baroud, et al.
Published: (2021-12-01)

Prolonged gastric mucosal haemorrhage following azacitidine administration in a patient with myelodysplastic syndrome
by: Hiroaki Kitamura, et al.
Published: (2021-08-01)

Dry Dressing for Epidermal Sloughing after Subcutaneous Azacitidine Injection in a Myelodysplastic Syndrome
by: Jun Yong Lee, et al.
Published: (2014-07-01)

An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum
by: Esra Turan Erkek, et al.
Published: (2016-02-01)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Fernando Vieira Pericole, et al.
Published: (2019-01-01)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
by: Myrna Candelaria-Hernández, et al.
Published: (2017-06-01)

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine
by: Daisuke Okamura, et al.
Published: (2014-01-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine
by: Kamel Laribi, et al.
Published: (2019-05-01)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
by: Jehad Almasri, et al.
Published: (2018-09-01)

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)
by: Sternberg, A, et al.
Published: (2022)

PB1917: PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF ELEMENTS OF THE ADAPTIVE IMMUNITY IN THE MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACITIDINE
by: Z. Tsakiraki, et al.
Published: (2022-06-01)

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS
by: S. P. Desikan, et al.
Published: (2022-06-01)

Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine
by: Carlo Pescia, et al.
Published: (2021-10-01)

P754: INITIAL RESULTS OF PHASE I/II STUDY OF AZACITIDINE IN COMBINATION WITH QUIZARTINIB FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH FLT3 OR CBL MUTATION
by: T. Abuasab, et al.
Published: (2022-06-01)

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes
by: Garcia-Manero, G, et al.
Published: (2021)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
by: Guillermo Garcia-Manero, et al.
Published: (2023-08-01)